当前位置:首页>产品中心>单抗/多抗>Anti-Human UBQLN4 Polyclonal Antibody|抗人UBQLN4多克隆抗体(靶标:人泛素蛋白2样4)

Anti-Human UBQLN4 Polyclonal Antibody|抗人UBQLN4多克隆抗体(靶标:人泛素蛋白2样4)

  • 货号:RB9THP715014
  • 价格:面议
  • 点击:507
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Mouse, Human
靶标Ubiquilin-4; Ataxin-1 interacting ubiquitin-like protein; A1Up; Ataxin-1 ubiquitin-like-interacting protein A1U; Connexin43-interacting protein of 75 kDa; CIP75; UBQLN4; C1orf6; CIP75; UBIN
免疫原E. coli - derived recombinant Human UBQLN4 (Pro12-Lys83).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q9NRR5
背景信息

Ubiquilin-4 (UBQLN4) is a ~63 kDa protein. Regulator of protein degradation that mediates the proteasomal targeting of misfolded, mislocalized or accumulated proteins. Acts by binding polyubiquitin chains of target proteins via its UBA domain and by interacting with subunits of the proteasome via its ubiquitin-like domain. Key regulator of DNA repair that represses homologous recombination repair: in response to DNA damage, recruited to sites of DNA damage following phosphorylation by ATM and acts by binding and removing ubiquitinated MRE11 from damaged chromatin, leading to MRE11 degradation by the proteasome. MRE11 degradation prevents homologous recombination repair, redirecting double-strand break repair toward non-homologous end joining (NHEJ). Specifically recognizes and binds mislocalized transmembrane-containing proteins and targets them to proteasomal degradation.

1. Riley, BE. et al. (2004) The Journal of biological chemistry 279, 42290-301. PMID: 15280365
2. Suzuki, R. et al. (2016) EMBO reports 17, 842-57. PMID: 27113755
3. Hirayama, S. et al. (2018) Proceedings of the National Academy of Sciences of the United States of America 115, E4199-E4208. PMID: 29666234
4. Jachimowicz, RD. et al. (2019) Cell 176, 505-519.e22. PMID: 30612738
5. Lee, DY. et al. (2013) EMBO reports 14, 373-81. PMID: 23459205
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 416
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 416
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 614
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 589
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 517
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 483
Anti-Daratumumab Non-Neutralizing Recombinant Antibody|抗达雷妥尤单抗非中和重组抗体(靶标:达雷妥尤单抗非中和抗体) 553
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 590
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 541
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 653
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 616
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 333
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 423
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 593
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 425
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 617
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 418
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 647
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 627
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 571
总计 33037 个记录,共 1652 页,当前第 1648 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00